ReMed 2018 ReMed N°6 - Addiction | Page 12

Sciences de la Santé References: 1- United Nations Office on Drugs and Crime. World Drug Report 2018. United Nations publication, Sales No. E.18.XI.9. Available from: https://www.unodc.org/wdr2018. 2- Strain E.Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, screening, assessment, and diagnosis. Uptodate 2018. 3- Schmitt S. Osteomyelitis. Infectious Disease Clinics of North America. 2017;31(2):325-338. 4- Berbari E, Kanj S, Kowalski T, Darouiche R, Widmer A, Schmitt S et al. 2015 Infectious Diseases Society of Ameri- ca (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clini- cal Infectious Diseases. 2015;61(6):e26-e46. 5- Sande MA, Lee BL, Mills J, et al. Endocarditis in intrave- nous drug users. In: Infective Endocarditis, Kaye D (Ed), Ra- ven Press, New York City 1992. p.345. 6- Quagliarello B, Cespedes C, Miller M, Toro A, Vavagiakis P, Klein R et al. Strains of Staphylococcus aureus Obtained from Drug-Use Networks Are Closely Linked. Clinical Infec- tious Diseases. 2002;35(6):671-677. 7- Gordon RJ, Lowy FD. Bacterial Infections in Drug Users. N Engl J Med 2005;353:1945-54. 12 Été 2018 8- Ryznar E, O’Gara PT, Lilly LS. Valvular Heart Disease. In: Pathophysiology of heart disease (Lilly), 6th edition, 2016. p.212. 9- Habib G, Lancellotti P, Antunes M, Bongiorni M, Casalta J, Del Zotti F et al. 2015 ESC Guidelines for the manage- ment of infective endocarditis. European Heart Journal. 2015;36(44):3075-3128. 10- Martı´n-Da´vila et al. Analysis of mortality and risk factors associated with native valve endocarditis in drug users: The importance of vegetation size. American Heart Journal.2015 ; 150(5) :1099-1106. 11- Joint United Nations Programme on HIV/AIDS. The GAP report. UNAIDS Information Production Unit. September 2014. Available from: http://www.unaids.org/sites/default/ files/media_asset/UNAIDS_Gap_report_en.pdf. 12- Tortu S, McMahon JM, Pouget ER, Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepa- titis C. Subst Use Misuse. 2004;39(2):211. 13- Edlin BR, Carden MR, FerrandoSJ. Managing Hepatitis C in Users of Illicit Drugs. Curr Hepat Rep. 2007 ; 6(2): 60–67. 14- Li H-C, Lo S-Y. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol 2015 June 8; 7(10): 1377-1389.